Kenvue Target of Unusually Large Options Trading (NYSE:KVUE)

Kenvue Inc. (NYSE:KVUE) saw unusually large options trading activity on Wednesday. Stock traders acquired 53,946 call options on the stock. This is an increase of approximately 623% compared to the average daily volume of 7,464 call options.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in KVUE. Grove Bank & Trust increased its stake in Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after buying an additional 947 shares during the period. Geneos Wealth Management Inc. acquired a new position in Kenvue in the 4th quarter valued at approximately $29,000. SRS Capital Advisors Inc. increased its stake in Kenvue by 67.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after buying an additional 571 shares during the period. Fortitude Family Office LLC increased its stake in Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after buying an additional 777 shares during the period. Finally, Ashton Thomas Securities LLC acquired a new position in Kenvue in the 3rd quarter valued at approximately $35,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Price Performance

Shares of NYSE:KVUE traded up $0.22 during trading on Wednesday, reaching $22.22. The company had a trading volume of 7,648,927 shares, compared to its average volume of 13,035,021. The firm’s fifty day moving average is $21.30 and its 200 day moving average is $22.12. The firm has a market capitalization of $42.59 billion, a PE ratio of 41.90, a price-to-earnings-growth ratio of 2.57 and a beta of 1.45. Kenvue has a twelve month low of $17.67 and a twelve month high of $24.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, equities analysts forecast that Kenvue will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be paid a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.69%. Kenvue’s dividend payout ratio is presently 154.72%.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $24.00 price objective on shares of Kenvue in a research report on Monday, February 3rd. Piper Sandler raised shares of Kenvue from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $21.00 to $26.00 in a research report on Monday, January 6th. UBS Group lowered their price objective on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research report on Friday, February 7th. Canaccord Genuity Group lowered their price objective on shares of Kenvue from $27.00 to $24.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Finally, Bank of America boosted their price objective on shares of Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research report on Tuesday, October 22nd. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $23.00.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.